IL307750A - Treatment of cutaneous lupus erythematous - Google Patents
Treatment of cutaneous lupus erythematousInfo
- Publication number
- IL307750A IL307750A IL307750A IL30775023A IL307750A IL 307750 A IL307750 A IL 307750A IL 307750 A IL307750 A IL 307750A IL 30775023 A IL30775023 A IL 30775023A IL 307750 A IL307750 A IL 307750A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- skin lupus
- erythematous skin
- erythematous
- lupus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
- A61M5/002—Packages specially adapted therefor, e.g. packages for syringes or needles or kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178750P | 2021-04-23 | 2021-04-23 | |
| PCT/EP2022/060669 WO2022223770A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of cutaneous lupus erythematous |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307750A true IL307750A (en) | 2023-12-01 |
Family
ID=81850041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307750A IL307750A (en) | 2021-04-23 | 2022-04-22 | Treatment of cutaneous lupus erythematous |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002589A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326322A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519196A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240000557A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117222430A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022261422A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021868A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216390A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307750A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317617A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022223770A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| GB202315831D0 (en) * | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643237T3 (es) * | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| SMT201700063T1 (it) | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
| CN104603152A (zh) * | 2012-06-13 | 2015-05-06 | 米迪缪尼有限公司 | 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案 |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| JP2023527054A (ja) * | 2020-05-29 | 2023-06-26 | アストラゼネカ・アクチエボラーグ | I型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 |
| TW202237647A (zh) * | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| SMT202300382T1 (it) * | 2021-04-23 | 2024-01-10 | Astrazeneca Ab | Regime di dosaggio anti-ifnar1 per iniezione sottocutanea |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
-
2022
- 2022-04-22 TW TW111115528A patent/TW202317617A/zh unknown
- 2022-04-22 AU AU2022261422A patent/AU2022261422A1/en active Pending
- 2022-04-22 WO PCT/EP2022/060669 patent/WO2022223770A1/en not_active Ceased
- 2022-04-22 IL IL307750A patent/IL307750A/en unknown
- 2022-04-22 CN CN202280029637.6A patent/CN117222430A/zh active Pending
- 2022-04-22 CA CA3216390A patent/CA3216390A1/en active Pending
- 2022-04-22 BR BR112023021868A patent/BR112023021868A2/pt unknown
- 2022-04-22 KR KR1020237040112A patent/KR20240000557A/ko active Pending
- 2022-04-22 JP JP2023564487A patent/JP2024519196A/ja active Pending
- 2022-04-22 EP EP22725714.4A patent/EP4326322A1/en active Pending
-
2024
- 2024-02-07 US US18/435,476 patent/US20250002589A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250002589A1 (en) | 2025-01-02 |
| CA3216390A1 (en) | 2022-10-27 |
| CN117222430A (zh) | 2023-12-12 |
| AU2022261422A1 (en) | 2023-11-30 |
| TW202317617A (zh) | 2023-05-01 |
| AU2022261422A9 (en) | 2023-12-07 |
| BR112023021868A2 (pt) | 2023-12-19 |
| JP2024519196A (ja) | 2024-05-09 |
| EP4326322A1 (en) | 2024-02-28 |
| WO2022223770A1 (en) | 2022-10-27 |
| KR20240000557A (ko) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286079A (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
| GB2572642B (en) | Treatment of diabetic foot ulcers | |
| JP1789738S (ja) | 皮膚治療機器 | |
| IL261809A (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| DK4255442T3 (da) | Jak-hæmmer med d-vitamin-analog til behandling af hudsygdomme | |
| EP3600374C0 (en) | TREATMENT OF A RESPIRATORY INFECTION | |
| SI3773558T1 (sl) | Kombinirano zdravljenje artritične bolezni | |
| EP4352231A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH ANGPTL4 | |
| EP4149453A4 (en) | COMBINATION TREATMENT OF LIVER DISEASES | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| EP3866795A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| JP1764702S (ja) | 皮膚治療装置 | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| JP1764978S (ja) | スキントリートメント器具 | |
| EP4413032A4 (en) | TREATMENT OF MAST CELL DISORDERS | |
| EP3703753A4 (en) | TREATMENT OF ALLERGIC DISEASES MEDIA BY IGE | |
| EP4081238A4 (en) | Treatment of mild traumatic brain injury | |
| GB202001353D0 (en) | Treatment of skin conditions | |
| KR20240099184A9 (ko) | 재생불량성 질환 치료를 위한 mrna 레귤론 요법 | |
| DK3863647T3 (da) | Behandling af ondartet knoglesmerte med pentosanpolysulfat | |
| EP4313024A4 (en) | Treatment of inflammatory diseases | |
| IL307205A (en) | Perilesional treatment of skin conditions | |
| IL282869A (en) | Use of tivozanib to treat subjects with refractory cancer | |
| EP4135553C0 (en) | SKIN TREATMENT SYSTEM | |
| MA56179A (fr) | Traitement de synucléinopathies |